Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors-Reference-Cited by-同舟云学术

Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors

Published:2018-09-21 Issue:11 Volume:12 Page:1838-1855
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Rye Inga H.¹,Trinh Anne²,Sætersdal Anna B.³,Nebdal Daniel¹,Lingjærde Ole Christian¹⁴,Almendro Vanessa⁵,Polyak Kornelia⁵,Børresen‐Dale Anne‐Lise¹⁶,Helland Åslaug¹³⁶,Markowetz Florian²,Russnes Hege G.¹⁷

Affiliation:

1. Department of Cancer Genetics Institute for Cancer Research Oslo University Hospital Radiumhospitalet Norway

2. Cancer Research UK Cambridge Institute University of Cambridge UK

3. Department of Oncology Oslo University Hospital Norway

4. Biomedical Informatics Division Department of Computer Science University of Oslo Norway

5. Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA

6. Department of Clinical Medicine University of Oslo Norway

7. Department of Pathology Oslo University Hospital Norway

Funder

National Institutes of Health

Kreftforeningen

Cancer Research UK

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12375

Reference36 articles.

1. HER-2 intratumoral heterogeneity

2. Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification

3. ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study

4. HeterogeneousHER2Gene Amplification

5. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives;Nature Reviews Clinical Oncology;2024-01-08

2. A multiscale model of the role of microenvironmental factors in cell segregation and heterogeneity in breast cancer development;PLOS Computational Biology;2023-11-22

3. Targeting HER2 heterogeneity in breast and gastrointestinal cancers;Trends in Cancer;2023-11

4. A convolutional neural network STIFMap reveals associations between stromal stiffness and EMT in breast cancer;Nature Communications;2023-06-15

5. HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept;Cancers;2023-05-09